Here are five observations:
1. Technology advancements and demand for minimally invasive surgery will spur the spine biologics market growth.
2. Additionally, the aging population, rising prevalence of disease and increasing government funding will also boost the market.
3. North America currently possesses the largest market share, but the Asia-Pacific region will likely see the most growth due to high populations.
4. The costliness of procedures as well as the availability of substitute products will serve as barriers to market growth.
5. Alphatec Spine, Medtronic, Zimmer Biomet, Globus Medical, Exactech, RTI Biologics, Small Bone Innovations, Stryker, Amedica, K2M, NuVasive, Precision Spine and TranS1 represent leaders in the market.
More articles on devices:
FDA clears Onkos Surgical’s ELEOS Limb Salvage System: 5 things to know
Positive 2-year results for Zimmer Biomet’s Aspen MIS Fusion System: 3 insights
Robotics & navigation technology grab spotlight at NASS meeting
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
